

Review of: "Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series"

Ivana Kolarov Bjelobrk

Potential competing interests: The author(s) declared that no potential competing interests exist.

A large number of patients were included in this study and different variables were analyzed. But I think there are too many data in the tables, which are difficult to read. Also in the era of new anti-HER 2 therapy, patients receiving pertuzumab and T-DMI, should be included.